MMC Healthcare, which has presence in the gynaecology, surgery and ortho segment at present, has launched two new products in the segments of gastro intestinal. The new products are Domz capsules (omiprazole entric coated granules -20 mg) and Domperidone- 10 mg is a combi-therapy for acid related disorder and dyspepsia. With the launch of the combi-therapy product, the company has forayed into the gastro-intestinal segment.
The other product launched is Septidase-D, contains serrapeptidase 15 mg with micrometals, and is a line extension of an existing product, Septidase, that the company currently manufactures and market. The concept of micrometals (cobalt, calcium, zinc and manganese along with diclofenac potassium) was first pioneered by the company in 1993 a helps in increasing the efficacy of the product by over 113 per cent of the original efficacy. Serrapeptidase being enzyme derived leads to decreased efficacy according to the formulation and other factors involved in therapy. If the same is taken along with mineral water the efficacy slumps to 60 per cent of the original efficacy. Micrometals helps to enhance the efficacy.
Both the products are to be marketed through the ethical route, according to the company sources. The product will be marketed in the seven states, viz, Tamil Nadu, Karnataka, Andhra Pradesh, Karnataka, Maharashtra, Orissa, and West Bengal, where the company currently operates. The company expects to rake in revenue of Rs. 2.5 to Rs. 2.8 crore from the two new products, according to the company sources.
Meanwhile, the company leveraging on the efficiency of the net has implemented a Web-based reporting system that will help in easy access to field reports and provide for efficient logistics. Developed by PMC Soft Limited, the company has spent Rs 1.25 lakh for implementing the system.
The company has also initiated measures to set up a cGMP compliant manufacturing facility at Thirumaizai near Chennai at an estimated cost of Rs 1.20 crore. The same is to be financed by internal accruals and term loan from the Tamil Nadu Industrial Investment Corporation (TIIC). The facility is to be commissioned in the second quarter of the next financial year.